{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T03:22:08Z","timestamp":1781839328475,"version":"3.54.5"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Artesunate is recommended by the World Health Organization (WHO) for parenteral\u00a0treatment of severe <jats:italic>Plasmodium falciparum<\/jats:italic> malaria. However, artesunate is inherently unstable in an aqueous solution and hydrolyses rapidly after its preparation for injection. Therefore, the aim of the study was to evaluate the stabilizing effects of phosphate buffer and mannitol against short-term (ex-tempore) artesunate hydrolysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A HPLC\u2013UV isocratic method was developed using a reversed-phase fused core column (HALO RP-C18) and a mobile phase consisting of a mixture of 45% ammonium formate 10\u00a0mM in water (pH 4.5) and 55% methanol. Artesunate was formulated as aqueous solutions using a design of experiment (DOE) to investigate the artesunate stabilizing effects of pH (8\u201310), phosphate buffer strength (0.3\u20130.5\u00a0M), and mannitol (0\u20130.22\u00a0mmol\/mL). The solutions were incubated at predefined temperatures (5, 25, and 40\u00a0\u00b0C) with subsequent analysis. Arrhenius equation was applied to model and evaluate the stability results.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The developed HPLC-based method using fused-core stationary phase allowed to selectively quantify artesunate in the presence of\u00a0its\u00a0main hydrolysis degradants; namely \u03b2-dihydroartemisinin (\u03b2-DHA) and \u03b1-dihydroartemisinin (\u03b1-DHA) within 10\u00a0min. By applying the Arrhenius equation, the rate of hydrolysis of the drug increased approximately by 3.4 as the temperature raised by 10\u00a0\u00b0C. Buffer strength was found to be the main factor affecting the hydrolysis rate constants at 5 and 25\u00a0\u00b0C (p\u2009&lt;\u20090.05), the activation energy (p\u2009=\u20090.009), and the frequency factor (p\u2009=\u20090.045). However, the effect of the buffer was predominant on the activation energy and hydrolysis rate constants, revealing its stabilizing effect on the drug at lower buffer strength (0.3\u00a0M). Within the investigated range (pH\u2009=\u20098\u201310), pH was found to influence the activation energy, with a positive stabilizing effect in the pH range of 8\u20139. The addition of mannitol as stabilizing agent into artesunate aqueous formulation did not show an improved response.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Phosphate buffer was\u00a0the main stability determining factor of artesunate in the aqueous intravenous (i.v.) formulation and was found to be more effective in stabilizing artesunate at a buffer strength of 0.3\u00a0M in pH 8\u20139, while mannitol lacked stabilizing effect.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12936-022-04278-4","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T15:20:55Z","timestamp":1662477655000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Degradation kinetics of artesunate for the development of an ex-tempore intravenous injection"],"prefix":"10.1186","volume":"21","author":[{"given":"Fanta","family":"Gashe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelien","family":"Wynendaele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"De Spiegeleer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sultan","family":"Suleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,6]]},"reference":[{"key":"4278_CR1","first-page":"602","volume":"66","author":"L Chekem","year":"2006","unstructured":"Chekem L, Wierucki S. [Extraction of artemisinin and synthesis of its derivates artesunate and artemether](in French). Med Trop (Mars). 2006;66:602\u20135.","journal-title":"Med Trop (Mars)"},{"key":"4278_CR2","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1007\/s00436-020-06786-1","volume":"119","author":"JO Adebayo","year":"2020","unstructured":"Adebayo JO, Tijjani H, Adegunloye AP, Ishola AA, Balogun EA, Malomo SO. Enhancing the antimalarial activity of artesunate. Parasitol Res. 2020;119:2749\u201364.","journal-title":"Parasitol Res"},{"key":"4278_CR3","doi-asserted-by":"publisher","first-page":"3778","DOI":"10.1002\/jcp.24086","volume":"227","author":"C Zhou","year":"2012","unstructured":"Zhou C, Pan W, Wang XP, Chen TS. Artesunate induces apoptosis via a Bak-mediated caspase-independent intrinsic pathway in human lung adenocarcinoma cells. J Cell Physiol. 2012;227:3778\u201386.","journal-title":"J Cell Physiol"},{"key":"4278_CR4","doi-asserted-by":"publisher","first-page":"33425","DOI":"10.1074\/jbc.M114.564567","volume":"28","author":"ND Yang","year":"2014","unstructured":"Yang ND, Tan S, Ng S, Shi Y, Zhou J, Tan KS, et al. Artesunate induces cell death in human cancer cells via enhancing lysosomal function and lysosomal degradation of ferritin. J Biol Chem. 2014;28:33425\u201341.","journal-title":"J Biol Chem"},{"key":"4278_CR5","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s00706-021-02759-x","volume":"152","author":"P Khanal","year":"2021","unstructured":"Khanal P. Antimalarial and anticancer properties of artesunate and other artemisinins: current development. Monatsh Chem. 2021;152:387\u2013400.","journal-title":"Monatsh Chem"},{"key":"4278_CR6","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.2022.36.S1.L8040","volume":"36","author":"J Fabian","year":"2022","unstructured":"Fabian J, Pierce T, Brown S, Payne G, Adedeji D. Preliminary assessment of the combination studies of artesunate with paclitaxel on human prostate cancer cell proliferation. FASEB J. 2022;36: l8040.","journal-title":"FASEB J"},{"key":"4278_CR7","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.3390\/cancers14051100","volume":"14","author":"S Kamran","year":"2022","unstructured":"Kamran S, Sinniah A, Abdulghani MAM, Alshawsh MA. Therapeutic potential of certain terpenoids as anticancer agents: a scoping review. Cancers. 2022;14:1100.","journal-title":"Cancers"},{"key":"4278_CR8","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.phrs.2016.02.017","volume":"110","author":"MEM Saeed","year":"2016","unstructured":"Saeed MEM, Krishna S, Greten HJ, Kremsner PG, Efferth T. Antischistosomal activity of artemisinin derivatives in vivo and in patients. Pharmacol Res. 2016;110:216\u201326.","journal-title":"Pharmacol Res"},{"key":"4278_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.actatropica.2021.106260","volume":"226","author":"N Intakhan","year":"2022","unstructured":"Intakhan N, Siriyasatien P, Chanmol W. Anti-Leishmania activity of artesunate and combination effects with amphotericin B against Leishmania (Mundinia) martiniquensis in vitro. Acta Trop. 2022;226: 106260.","journal-title":"Acta Trop"},{"key":"4278_CR10","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3390\/jcm6030030","volume":"6","author":"WH Choi","year":"2017","unstructured":"Choi WH. Novel pharmacological activity of artesunate and artemisinin: their potential as anti-tubercular agents. J Clin Med. 2017;6:30.","journal-title":"J Clin Med"},{"key":"4278_CR11","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1086\/591195","volume":"47","author":"T Efferth","year":"2008","unstructured":"Efferth T, Romero RM, Wolf DG, Stamminger T, Marin JJ, Marschall M. The antiviral activities of artemisinin and artesunate. Clin Infect Dis. 2008;47:804\u201311.","journal-title":"Clin Infect Dis"},{"key":"4278_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jksus.2021.101810","volume":"32","author":"AB Gurung","year":"2022","unstructured":"Gurung AB, Ali MA, Lee J, Farah MA, Al-Anazi KM, Al-Hemaid F. Artesunate induces substantial topological alterations in the SARS-CoV-2 Nsp1 protein structure. J King Saud Univ Sci. 2022;32: 101810.","journal-title":"J King Saud Univ Sci"},{"key":"4278_CR13","unstructured":"WHO. Guidelines for malaria. Geneva, World Health Organization, 2021. [http:\/\/apps.who.int\/iris] [Assessed on June 13, 2022]."},{"key":"4278_CR14","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.3390\/ph3072322","volume":"3","author":"Q Li","year":"2010","unstructured":"Li Q, Weina P. Artesunate: the best drug in the treatment of severe and complicated malaria. Pharmaceuticals (Basel). 2010;3:2322\u201332.","journal-title":"Pharmaceuticals (Basel)"},{"key":"4278_CR15","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1016\/S0140-6736(10)61924-1","volume":"376","author":"AM Dondorp","year":"2010","unstructured":"Dondorp AM, Fanello CI, Hendriksen IC, Gomes E, Seni A, Chhaganlal KD, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet. 2010;376:1647\u201357.","journal-title":"Lancet"},{"key":"4278_CR16","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1471-2210-1-12","volume":"1","author":"PL Olliaro","year":"2001","unstructured":"Olliaro PL, Nair NK, Sathasivam K, Mansor SM, Navaratnam V. Pharmacokinetics of artesunate after single oral administration to rats. BMC Pharmacol. 2001;1:12.","journal-title":"BMC Pharmacol"},{"key":"4278_CR17","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/1475-2875-10-263","volume":"10","author":"CA Morris","year":"2011","unstructured":"Morris CA, Duparc S, Borghini-Fuhrer I, Jung D, Shin CS, Fleckenstein L. Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. Malar J. 2011;10:263.","journal-title":"Malar J"},{"key":"4278_CR18","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1002\/cmdc.200600240","volume":"2","author":"M Schlitzer","year":"2007","unstructured":"Schlitzer M. Malaria chemotherapeutics part I: History of antimalarial drug development, currently used therapeutics, and drugs in clinical development. ChemMedChem. 2007;2:944\u201386.","journal-title":"ChemMedChem"},{"key":"4278_CR19","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/j.2042-7158.1996.tb05870.x","volume":"48","author":"KT Batty","year":"1996","unstructured":"Batty KT, Ilett KF, Davis T, Davis ME. Chemical stability of artesunate injection and proposal for its administration by intravenous infusion. J Pharm Pharmacol. 1996;48:22\u20136.","journal-title":"J Pharm Pharmacol"},{"key":"4278_CR20","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/1475-2875-11-S1-P99","volume":"11","author":"K Van Acker","year":"2012","unstructured":"Van Acker K, Mommaerts M, Vanermen S, Meskens J, Vander Heyden Y, Plaizier-Vercammen J. Chemical stability of artemisinin derivatives. Malar J. 2012;11:99.","journal-title":"Malar J"},{"key":"4278_CR21","first-page":"117","volume":"6","author":"J Agnihotri","year":"2013","unstructured":"Agnihotri J, Singh S, Bigonia P. Formal chemical stability analysis and solubility analysis of artesunate and hydroxychloroquinine for development of parenteral dosage form. J Pharm Res. 2013;6:117\u201322.","journal-title":"J Pharm Res"},{"key":"4278_CR22","unstructured":"WHO. Guidelines for the treatment of malaria: 2nd Edn. Geneva, World Health Organization, 2010. [http:\/\/whqlibdoc.who.int\/publications\/2010\/9789241547925_ eng.pdf] [Assessed on April 20, 2021)."},{"key":"4278_CR23","unstructured":"WHO-PQ recommended summary characteristics of artesunate powder for injection [https:\/\/extranet.who.int\/pqweb\/sites\/default\/files\/MA090part4.pdf]. Assessed 05 Nov 2021]"},{"key":"4278_CR24","unstructured":"Pramanick S, SingodiaD, Chandel V. Excipient selection in parenteral formulation development. Pharm Times. 2013;45."},{"key":"4278_CR25","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1080\/03639045.2018.1483392","volume":"44","author":"BM Rayaprolu","year":"2018","unstructured":"Rayaprolu BM, Strawser SJ, Anyarambhatla G. Excipients in parenteral formulations: selection considerations and effective utilization with small molecules and biologics. Drug Dev Ind Pharm. 2018;44:1565\u201371.","journal-title":"Drug Dev Ind Pharm"},{"key":"4278_CR26","first-page":"41","volume":"1","author":"A Baheti","year":"2010","unstructured":"Baheti A, Kumar L, Bansal AK. Excipients used in lyophilization of small molecules. J Excip Food Chem. 2010;1:41\u201354.","journal-title":"J Excip Food Chem"},{"key":"4278_CR27","volume-title":"Handbook of pharmaceutical excipients","author":"RC Rowe","year":"2012","unstructured":"Rowe RC, Sheskey PJ, Owen SC. Handbook of pharmaceutical excipients. 7th ed. London: Pharmaceutical Press; 2012.","edition":"7"},{"key":"4278_CR28","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1248\/cpb.c12-01025","volume":"61","author":"T Ogawa","year":"2013","unstructured":"Ogawa T, Miyajima M, Wakiyama N, Terada K. Effects of phosphate buffer in parenteral drugs on particle formation from glass vials. Chem Pharm Bull. 2013;61:539\u201345.","journal-title":"Chem Pharm Bull"},{"key":"4278_CR29","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40543-022-00317-6","volume":"13","author":"D Bhangare","year":"2022","unstructured":"Bhangare D, Rajput N, Jadav T, Kumar AS, Tekade RK, Sengupta P. Systematic strategies for degradation kinetic study of pharmaceuticals: an issue of utmost importance concerning current stability analysis practices. J Anal Sci Technol. 2022;13:7.","journal-title":"J Anal Sci Technol"},{"key":"4278_CR30","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/dta.1656","volume":"7","author":"V Agrahari","year":"2015","unstructured":"Agrahari V, Putty S, Mathes C, Murowchick JB, Youan BB. Evaluation of degradation kinetics and physicochemical stability of tenofovir. Drug Test Anal. 2015;7:207\u201313.","journal-title":"Drug Test Anal"},{"key":"4278_CR31","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/jssc.200800437","volume":"32","author":"K Gaudin","year":"2009","unstructured":"Gaudin K, Kauss T, Lagueny AM, Millet P, Fawaz F, Dubost JP. Determination of artesunate using reversed-phase HPLC at increased temperature and ELSD detection. J Sep Sci. 2009;32:231\u20137.","journal-title":"J Sep Sci"},{"key":"4278_CR32","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1093\/chromsci\/bmaa037","volume":"58","author":"MA Saeed","year":"2020","unstructured":"Saeed MA, Ansari MT, Ch BA, Zaman M. RP-HPLC Method for the determination and quantification of artesunate. J Chromatogr Sci. 2020;58:695\u20139.","journal-title":"J Chromatogr Sci"},{"key":"4278_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijpharm.2007.10.048","volume":"353","author":"K Gaudin","year":"2008","unstructured":"Gaudin K, Barbaud A, Boyer C, Langlois MH, Lagueny AM, Dubost JP, et al. In vitro release and stability of an artesunate rectal gel suitable for pediatric use. Int J Pharm. 2008;353:1\u20137.","journal-title":"Int J Pharm"},{"key":"4278_CR34","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/1475-2875-12-145","volume":"12","author":"S Suleman","year":"2013","unstructured":"Suleman S, Vandercruyssen K, Wynendaele E, D\u2019Hondt M, Bracke N, Duchateau L, et al. A rapid stability-indicating, fused-core HPLC method for simultaneous determination of \u03b2-artemether and lumefantrine in anti-malarial fixed-dose combination products. Malar J. 2013;12:145.","journal-title":"Malar J"},{"key":"4278_CR35","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jpha.2013.09.003","volume":"4","author":"M Blessy","year":"2014","unstructured":"Blessy M, Patel RD, Prajapati PN, Agrawal YK. Development of forced degradation and stability indicating studies of drugs\u2014a review. J Pharm Anal. 2014;4:159\u201365.","journal-title":"J Pharm Anal"},{"key":"4278_CR36","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.3390\/molecules27092958","volume":"27","author":"LA Shervington","year":"2022","unstructured":"Shervington LA, Ingham O. Investigating the stability of six phenolic TMZ ester analogues, incubated in the presence of porcine liver esterase and monitored by HPLC. Molecules. 2022;27:2958.","journal-title":"Molecules"},{"key":"4278_CR37","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jpba.2015.01.014","volume":"107","author":"M Fu","year":"2015","unstructured":"Fu M, Perlman M, Lu Q, Varga C. Pharmaceutical solid-state kinetic stability investigation by using moisture-modified Arrhenius equation and JMP statistical software. J Pharm Biomed Anal. 2015;107:370\u20137.","journal-title":"J Pharm Biomed Anal"},{"key":"4278_CR38","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.scitotenv.2013.06.027","volume":"466\u2013467","author":"SM Mitchell","year":"2014","unstructured":"Mitchell SM, Ullman JL, Teel AL, Watts RJ. pH and temperature effects on the hydrolysis of three \u03b2-lactam antibiotics: ampicillin, cefalotin, and cefoxitin. Sci Total Environ. 2014;466\u2013467:547\u201355.","journal-title":"Sci Total Environ"},{"key":"4278_CR39","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.jpba.2004.03.017","volume":"35","author":"A Jeli\u0144ska","year":"2004","unstructured":"Jeli\u0144ska A, Dobrowolski L, Oszczapowicz I. The influence of pH, temperature and buffers on the degradation kinetics of cefetamet pivoxil hydrochloride in aqueous solutions. J Pharm Biomed Anal. 2004;35:1273\u2013127742.","journal-title":"J Pharm Biomed Anal"},{"key":"4278_CR40","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.ijpharm.2019.02.019","volume":"560","author":"L Samuelsen","year":"2019","unstructured":"Samuelsen L, Holm R, Lathuile A, Sch\u00f6nbeck JCS. Buffer solutions in drug formulation and processing: how pKa values depend on temperature, pressure and ionic strength. Int J Pharm. 2019;560:357\u201364.","journal-title":"Int J Pharm"},{"key":"4278_CR41","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1021\/ed084p38","volume":"84","author":"A Ault","year":"2007","unstructured":"Ault A. General acid and general base catalysis. J Chem Edu. 2007;84:38\u20139.","journal-title":"J Chem Edu"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-022-04278-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-022-04278-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-022-04278-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T15:24:07Z","timestamp":1662477847000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-022-04278-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,6]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["4278"],"URL":"https:\/\/doi.org\/10.1186\/s12936-022-04278-4","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,6]]},"assertion":[{"value":"19 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"256"}}